Pharmacotherapy
Participants randomized to UC received 18 weeks of 24-hour 21 mg NP. Participants randomized to ADT received 2 weeks of 24-hour 21 mg NP at baseline and up to 2 pharmacotherapy adaptations, with a first switch to varenicline and a second switch, if needed, to bupropion + NP based on CO-verified smoking status (CO ≥6 ppm) at weeks 2 and 6. Medications were dispensed at weeks 0, 2, and 6, with TQDs occurring at weeks 1, 3, and 7. The week 2 adaptation occurred after 2 weeks of patch therapy and 1 week after the first TQD. The week 6 adaptation occurred after 4 weeks of varenicline therapy and 3 weeks after the second TQD, allowing 1 week to titrate to the full dose of varenicline and 3 weeks of a quit attempt after reaching the full dose. Medication selection and order included NP because it is available over the counter and is the most used among Black adults who smoke,ADT participants with a CO status of 5 ppm